ArticleThe Journal of clinical endocrinology and metabolism2026
Long-Term Outcomes of Patients Diagnosed With Differentiated Thyroid Cancer in Childhood and Young Adulthood.
Article in The Journal of clinical endocrinology and metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Risk stratification and long-term monitoring in pediatric thyroid cancer: predictive markers for disease persistence.European thyroid journal · 2026Article
- Long-Term Outcomes of Patients Diagnosed With Differentiated Thyroid Cancer in Childhood and Young Adulthood.The Journal of clinical endocrinology and metabolism · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
contextRates of pediatric differentiated thyroid cancer (DTC) in the United States have been increasing while studies on this population remain limited by inconsistent age cutoffs, short follow-up periods, or relative lack of clinical data.
objectiveThis work aimed to report long-term outcomes in patients diagnosed with DTC at age 20 years and younger.
methodsA retrospective study was conducted of patients diagnosed with DTC at age 20 years or younger with long-term follow-up.
resultsA total of 155 patients were included with a median age at diagnosis of 17 years (9-20 years). The frequency of distant metastasis and larger tumor size were inversely related to age at diagnosis (overall stage P = .045; T-stage (size of the primary tumor ± invasion); P = .001). The median duration of follow-up was 16 years (1-63 years) and at last follow-up, 52.3% of patients had excellent response and disease specific mortality was 0%. There was no difference in response to therapy based on histologic subtype or birth sex; however, younger age at diagnosis was associated with worse response (P = .046). Patients with more than 50 years of follow-up (n = 9) had a median of 36 years of stability, with progression occurring in 6 out of 9 (67%) patients.
conclusionPatients diagnosed with DTC as children or young adults have outstanding long-term survivorship, but may experience disease progression later in life, suggesting that long-term follow-up might be appropriate for this population. Younger age at diagnosis was identified as a risk factor for distant metastases and poorer response to therapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.